Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + Tislelizumab vs Durvalumab after cCRT in unresectable stage III NSCLC (PD-L1–selected)
CTR20212322Phase 3Terminated
- Sponsor
- BeOne Medicines
- Start
- Sep 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Ociperlimab + Tislelizumab with Durvalumab (2 arms). Primary endpoint: Progression-free survival (PFS) by IRC in PD-L1 ≥50% and ≥1% populations. Started Sep 2021; status: terminated.
02
Drugs
ociperlimabtislelizumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212322.